SNGX - ソリジェニックス （Soligenix Inc.） ソリジェニックスSNGXのチャート
SNGXの企業情報
| symbol | SNGx |
|---|---|
| 会社名 | Soligenix Inc （ソリジェニックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Soligenix Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL) formulations of oral beclomethasone 17 21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation and its innate defense regulator (IDR) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax its ricin toxin vaccine candidate OrbeShield its GI acute radiation syndrome (GI ARS) therapeutic candidate and SGX943 its melioidosis therapeutic candidate. ソリジェニックスは米国のバイオ医薬品企業。後期の臨床段階で、がん治療法やワクチンの開発に従事。皮膚T細胞リンパ腫の治療に経口べクロメタゾン、胃腸障害の治療にニプロピオン酸塩、頭頚部がん治療に「Dusquetide(SGX942)」などを開発する。ワクチン部門ではリシン毒素ワクチン候補などの開発を行う。本社はニュ―ジャ―ジ―州プリンストン。 Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. |
| 本社所在地 | 29 Emmons Drive Suite C-10 Princeton NJ 08540 USA |
| 代表者氏名 | Christopher J. Schaber Christopher J. Schaber |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 609-538-8200 |
| 設立年月日 | 31778 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 16人 |
| url | www.soligenix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/sngx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -7.47089 |
| 終値（lastsale） | 1.8725 |
| 時価総額（marketcap） | 33111116.0275 |
| 時価総額 | 時価総額（百万ドル） 25.10963 |
| 売上高 | 売上高（百万ドル） 5.95594 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 20.86476 |
| 当期純利益 | 当期純利益（百万ドル） -7.03559 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Soligenix Inc revenues increased 23% to $2.8M. Net loss decreased 3% to $3.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects General and administrative decrease of 14% to $1.4M (expense) Interest income net of expense increase from $10K to $50K (income) Research and development decrease of 1% to $3M (expense). |
SNGXのテクニカル分析
SNGXのニュース
Soligenix stock jumps on filing seeking FDA approval of photodynamic therapy for cancer 2022/12/15 13:44:53 Seeking Alpha
Soligenix (SNGX) said it submitted a new drug application ((NDA)) to the U.S
The Investor Summit: Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference 2022/11/11 14:32:00 Finanz Nachrichten
Princeton, New Jersey--(Newsfile Corp. - November 11, 2022) - Investor Summit Group, today announced that Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company) will attend the Q4 Investor Summ…
Soligenix GAAP EPS of -$0.08 beats by $0.01, revenue of $0.2M in-line 2022/11/10 13:38:02 Seeking Alpha
Soligenix press release (SNGX): Q3 GAAP EPS of -$0.08 beats by $0.01.Revenue of $0.2M in-line (flat Y/Y).As of September 30, 2022, the Company''s cash position was approximately…
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results 2022/11/10 12:30:00 PR Newswire
PRINCETON, N.J., Nov. 10, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent…
Soligenix Enters Q4 With Multiple Catalysts in Play 2022/10/13 13:05:17 The Fintech Buzz
New York, New York–(Newsfile Corp. – October 13, 2022) – PCG Digital — Late-stage biopharmaceutical company, Soligenix, Inc. (NASDAQ: SNGX) is anticipating significant catalysts in Q4 and a potentially transformational […]
Recap: Soligenix Q2 Earnings 2022/08/12 13:17:39 Benzinga
Soligenix (NASDAQ: SNGX ) reported its Q2 earnings results on Friday, August 12, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Soligenix beat estimated earnings by 25.0%, reporting an EPS of $-0.06 versus … Full story available on Benzinga.com
Soligenix GAAP EPS of -$0.06 beats by $0.03, revenue of $0.4M beats by $0.2M 2022/08/12 12:06:14 Seeking Alpha
Soligenix press release (SNGX): Q2 GAAP EPS of -$0.06 beats by $0.03.Revenue of $0.4M (+100.0% Y/Y) beats by $0.2M.As of June 30, 2022, the Company''s cash position was…
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results 2022/08/12 11:30:00 PR Newswire
PRINCETON, N.J., Aug. 12, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent…
Soligenix Inc. (SNGX) Is Worth Thinking About For The Coming Weeks 2022/07/30 15:30:00 Stocks Register
Soligenix Inc. (NASDAQ:SNGX) price on Friday, July 29, fall -2.85% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $0.88. A look at the stock’s price movement, the close in the last trading session was $0.90, moving within a range at $0.861 and $0.92. The beta value (5-Year … Soligenix Inc. (SNGX) Is Worth Thinking About For The Coming Weeks Read More »
Soligenix gets agreement from FDA for photodynamic therapy study in kids for lymphoma 2022/07/27 12:22:15 Seeking Alpha
Soligenix (SNGX) said it received agreement from the U.S
Soligenix Gets FDA Nod For Mid-Stage Psoriasis Study 2022/06/28 14:07:34 Benzinga
The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s (NASDAQ: SNGX ) Investigational New Drug (IND) application for Phase 2a clinical trial Evaluating SGX302 in the treatment of patients with Mild-to-Moderate Psoriasis. This study is designed to evaluate the safety and efficacy of topically-applied SGX302 (synthetic hypericin), will enrol up to 32 patients age 18 years … Full story available on Benzinga.com
Soligenix adds 11% FDA nod to start mid-stage trial for psoriasis candidate 2022/06/28 11:57:18 Seeking Alpha
Clinical-stage biotech Soligenix (SNGX) added ~11% in the pre-market Tuesday after the company announced that the FDA cleared its investigational new drug ((IND)) application to start…
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis 2022/06/07 13:04:36 The Fintech Buzz
Strategy supports global need and has potential use in growing home healthcare market New York, New York–(Newsfile Corp. – June 7, 2022) – PCG Digital — Rising to the challenge in 2022, late-stage biopharma company Soligenix (NASDAQ: SNGX) continues to move forward with developing and commercializing products to treat rare diseases where there is an […]
Soligenix to Present at the H.C. Wainwright Global Investment Conference 2022/05/18 11:30:00 PR Newswire
PRINCETON, N.J., May 18, 2022 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the Company…